JMCP Supplements: AHRQ Comparative Effectiveness Reviews

A total of 6.25 hours of continuing education credit for pharmacists, nurses and physicians is available in 4 JMCP supplements created by the medical education company PRIME under contract with the Agency for Healthcare Research and Quality (AHRQ) to increase awareness and usefulness of AHRQ-sponsored reviews of findings in patient-centered outcomes research, also known as comparative effectiveness reviews (CERs). 

“AHRQ’s Comparative Effectiveness Research on Oral Medications for Type 2 Diabetes: A Summary of the Key Findings” - JMCP January/February 2012, 1.25 contact hour of CE/CME/CNE accreditation.  

 "Updates on the Treatment of Essential Hypertension: A Summary of AHRQ’s Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Direct Renin Inhibitors"  - JMCP October 2011, 1.0 contact hour of CE/CME/CNE accreditation.  

 “Summary of AHRQ’s Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease”  - JCMP June 2011, 1.0 contact hour of CE/CME/CNE accreditation.  

 “AHRQ’s Comparative Effectiveness Research on Premixed Insulin Analogues for Adults with Type 2 Diabetes: Understanding and Applying the Systematic Review Findings”  - JCMP April 2011, 3.0 contact hours of CE/CME/CNE accreditation.